Antonio C Wolff Selected Research

human ERBB2 protein

1/2022	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
10/2021	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
10/2021	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
1/2021	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
12/2020	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
10/2020	TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
1/2019	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
1/2019	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
1/2019	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
1/2019	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonio C Wolff Research Topics

Disease

154	Breast Neoplasms (Breast Cancer) 04/2022 - 01/2002
91	Neoplasms (Cancer) 01/2022 - 01/2002
10	Triple Negative Breast Neoplasms 10/2021 - 08/2009
9	Pathologic Complete Response 10/2021 - 02/2010
6	Diarrhea 06/2020 - 05/2011
5	Cardiotoxicity 02/2022 - 01/2002
5	Amenorrhea 08/2021 - 01/2005
4	Neutropenia 01/2021 - 01/2003
4	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 02/2003
4	Brain Neoplasms (Brain Tumor) 01/2020 - 08/2014
4	Disease Progression 01/2020 - 10/2011
4	Exanthema (Rash) 01/2019 - 03/2004
3	Fatigue 01/2021 - 01/2018
3	Hand-Foot Syndrome 06/2020 - 05/2010
2	Infertility (Sterility) 08/2021 - 06/2015
2	Infections 10/2020 - 07/2006
2	Hyperglycemia 01/2019 - 01/2018
2	Neurologic Manifestations (Neurological Manifestations) 01/2019 - 03/2016
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2019 - 09/2003
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 02/2015
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 02/2015
2	Osteoporosis 07/2016 - 01/2005
2	Pain (Aches) 07/2016 - 02/2012
2	Chronic Disease (Chronic Diseases) 01/2016 - 12/2015
2	Heart Failure 12/2015 - 01/2015
2	Obesity 07/2015 - 12/2012
2	Hypersensitivity (Allergy) 10/2014 - 12/2009
2	Vomiting 05/2013 - 04/2011
2	Cardiovascular Diseases (Cardiovascular Disease) 02/2012 - 02/2010
2	Nausea 05/2011 - 04/2011
2	Human Influenza (Influenza) 04/2009 - 03/2009
2	Colorectal Neoplasms (Colorectal Cancer) 04/2009 - 03/2009

Drug/Important Bio-Agent (IBA)

36	Trastuzumab (Herceptin)FDA Link 02/2022 - 01/2002
36	Hormones (Hormone)IBA 01/2022 - 01/2005
27	human ERBB2 proteinIBA 01/2022 - 01/2007
25	Estrogen ReceptorsIBA 01/2022 - 01/2007
17	Paclitaxel (Taxol)FDA LinkGeneric 02/2022 - 01/2003
17	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2008
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2009
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2020 - 03/2004
14	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2020 - 03/2004
13	Lapatinib (GW572016)FDA Link 01/2021 - 05/2008
10	Estrogens (Estrogen)FDA Link 01/2020 - 09/2007
9	Capecitabine (Xeloda)FDA Link 10/2021 - 05/2009
9	Aromatase InhibitorsIBA 10/2021 - 01/2005
9	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 09/2009
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2007
7	AnthracyclinesIBA 10/2018 - 01/2002
7	taxaneIBA 10/2018 - 04/2008
6	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 06/2012
6	Tamoxifen FDA LinkGeneric 07/2016 - 03/2004
6	Docetaxel (Taxotere)FDA Link 07/2015 - 03/2004
5	Letrozole (Femara)FDA LinkGeneric 01/2020 - 12/2012
5	Methotrexate (Mexate)FDA LinkGeneric 10/2019 - 01/2008
4	Ado-Trastuzumab EmtansineIBA 02/2022 - 01/2021
4	pertuzumabIBA 10/2021 - 01/2018
4	neratinibIBA 01/2020 - 03/2016
4	Fluorouracil (Carac)FDA LinkGeneric 10/2019 - 01/2008
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2019 - 11/2006
4	SodiumIBA 07/2011 - 12/2004
3	CytokinesIBA 02/2022 - 10/2014
3	Histone Deacetylase InhibitorsIBA 10/2021 - 01/2015
3	exemestane (Aromasin)FDA Link 10/2021 - 12/2012
3	VaccinesIBA 10/2020 - 12/2009
3	LipidsIBA 01/2020 - 12/2012
3	Everolimus FDA Link 01/2018 - 01/2013
3	Indicators and Reagents (Reagents)IBA 01/2016 - 12/2007
3	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2008 - 02/2007
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 12/2020
2	olaparibIBA 01/2022 - 12/2020
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 12/2020
2	palbociclibIBA 01/2022 - 01/2021
2	Cyclin-Dependent Kinase 4IBA 01/2022 - 01/2017
2	entinostat (MS 275)IBA 10/2021 - 06/2017
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2003
2	Hematoxylin (Haematoxylon)IBA 01/2020 - 09/2014
2	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 12/2010
2	Biological ProductsIBA 12/2019 - 10/2011
2	APTIBA 07/2019 - 06/2015
2	Fulvestrant (Faslodex)FDA Link 01/2019 - 01/2018
2	Phenobarbital (Luminal)FDA Link 01/2019 - 12/2018
2	Albumin-Bound Paclitaxel FDA Link 06/2015 - 01/2015
2	Monoclonal AntibodiesIBA 06/2015 - 04/2012
2	Carboplatin (JM8)FDA LinkGeneric 01/2015 - 07/2012
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2014 - 12/2009
2	Circulating Tumor DNAIBA 04/2014 - 06/2012
2	temsirolimus FDA Link 06/2013 - 01/2013
2	Protons (Proton)IBA 07/2011 - 12/2004
2	trans-sodium crocetinate (crocetin)IBA 07/2011 - 12/2007
2	CholesterolIBA 04/2009 - 03/2009
2	Taxoids (Taxanes)IBA 04/2008 - 09/2005
2	TubulinIBA 06/2004 - 11/2003

Therapy/Procedure

85	Therapeutics 04/2022 - 01/2002
41	Drug Therapy (Chemotherapy) 02/2022 - 09/2005
17	Adjuvant Chemotherapy 01/2021 - 07/2002
7	Neoadjuvant Therapy 02/2022 - 09/2010
4	Segmental Mastectomy (Lumpectomy) 08/2020 - 05/2007
4	Mastectomy (Mammectomy) 08/2020 - 02/2003
3	Radiotherapy 01/2019 - 04/2014
2	Ovariectomy (Oophorectomy) 01/2008 - 02/2007